TABLE 3.
P2-Leu substitutions of VP60-2 and PΩ-Ile substitutions of VP60-10
| Namea | Sequenceb | Refoldingc |
|
|---|---|---|---|
| RLA-A1 | HLA-A*0201 | ||
| VP60-2-WT | ALMPGQFFV | + | + |
| VP60-2-L2F | AFMPGQFFV | − | − |
| VP60-2- L2Q | AQMPGQFFV | − | + |
| VP60-2-L2S | ASMPGQFFV | − | + |
| VP60-2-L2T | ATMPGQFFV | − | + |
| VP60-2-L2Y | AYMPGQFFV | − | − |
| VP60-2-L2I | AIMPGQFFV | + | + |
| VP60-2-L2M | AMMPGQFFV | + | + |
| VP60-2-L2V | AVMPGQFFV | + | + |
| VP60-10-WT | FVPFNSPNI | + | + |
| VP60-10-I9F | FVPFNSPNF | − | − |
| VP60-10-I9Q | FVPFNSPNQ | − | − |
| VP60-10-I9Y | FVPFNSPNY | − | − |
| VP60-10-I9L | FVPFNSPNL | + | + |
| VP60-10-I9M | FVPFNSPNM | − | + |
| VP60-10-I9V | FVPFNSPNV | + | + |
a
WT, wild type.
b
The substitutions in the mutant peptides are underlined.
c
Peptides that can (+) or cannot (−) help the RLA-A1 heavy chain renature with human β2m.